Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Gary MoJohn R BaldwinDebra Luffer-AtlasRobert L IlariaIlaria ContiMichael HeathmanDamien M CronierPublished in: Clinical pharmacokinetics (2019)
The PKs of olaratumab were best described by a model with linear disposition. Patient body weight and tumor size were found to be significant covariates. The PKs of olaratumab were not affected by immunogenicity or chemotherapeutic agents.